Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease
- PMID: 16179381
- DOI: 10.1210/me.2005-0287
Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease
Abstract
Androgen-dependent prostate diseases initially require 5alpha-dihydrotestosterone (DHT) for growth. The DHT product 5alpha-androstane-3alpha,17beta-diol (3alpha-diol), is inactive at the androgen receptor (AR), but induces prostate growth, suggesting that an oxidative 3alpha-hydroxysteroid dehydrogenase (HSD) exists. Candidate enzymes that posses 3alpha-HSD activity are type 3 3alpha-HSD (AKR1C2), 11-cis retinol dehydrogenase (RODH 5), L-3-hydroxyacyl coenzyme A dehydrogenase , RODH like 3alpha-HSD (RL-HSD), novel type of human microsomal 3alpha-HSD, and retinol dehydrogenase 4 (RODH 4). In mammalian transfection studies all enzymes except AKR1C2 oxidized 3alpha-diol back to DHT where RODH 5, RODH 4, and RL-HSD were the most efficient. AKR1C2 catalyzed the reduction of DHT to 3alpha-diol, suggesting that its role is to eliminate DHT. Steady-state kinetic parameters indicated that RODH 4 and RL-HSD were high-affinity, low-capacity enzymes whereas RODH 5 was a low-affinity, high-capacity enzyme. AR-dependent reporter gene assays showed that RL-HSD, RODH 5, and RODH 4 shifted the dose-response curve for 3alpha-diol a 100-fold, yielding EC(50) values of 2.5 x 10(-9) M, 1.5 x 10(-9) M, and 1.0 x 10(-9) M, respectively, when compared with the empty vector (EC(50) = 1.9 x 10(-7) M). Real-time RT-PCR indicated that L-3-hydroxyacyl coenzyme A dehydrogenase and RL-HSD were expressed more than 15-fold higher compared with the other candidate oxidative enzymes in human prostate and that RL-HSD and AR were colocalized in primary prostate stromal cells. The data show that the major oxidative 3alpha-HSD in normal human prostate is RL-HSD and may be a new therapeutic target for treating prostate diseases.
Similar articles
-
Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.Endocrinology. 2003 Jul;144(7):2922-32. doi: 10.1210/en.2002-0032. Endocrinology. 2003. PMID: 12810547
-
Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.J Endocrinol. 2006 Dec;191(3):637-49. doi: 10.1677/joe.1.06365. J Endocrinol. 2006. PMID: 17170221
-
Modulation of the androgenic response by recombinant human 11-cis retinol dehydrogenase.J Steroid Biochem Mol Biol. 2001 May;77(2-3):129-33. doi: 10.1016/s0960-0760(01)00038-3. J Steroid Biochem Mol Biol. 2001. PMID: 11377978
-
Pre-receptor regulation of the androgen receptor.Mol Cell Endocrinol. 2008 Jan 16;281(1-2):1-8. doi: 10.1016/j.mce.2007.10.008. Epub 2007 Oct 22. Mol Cell Endocrinol. 2008. PMID: 18060684 Free PMC article. Review.
-
Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor.Mol Cell Endocrinol. 2007 Feb;265-266:77-82. doi: 10.1016/j.mce.2006.12.007. Epub 2007 Jan 16. Mol Cell Endocrinol. 2007. PMID: 17223255 Free PMC article. Review.
Cited by
-
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).J Steroid Biochem Mol Biol. 2015 Sep;153:105-13. doi: 10.1016/j.jsbmb.2015.05.010. Epub 2015 May 29. J Steroid Biochem Mol Biol. 2015. PMID: 26032458 Free PMC article. Review.
-
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.J Biol Chem. 2015 Aug 21;290(34):20865-20879. doi: 10.1074/jbc.M115.662155. Epub 2015 Jul 9. J Biol Chem. 2015. PMID: 26160177 Free PMC article.
-
Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.J Steroid Biochem Mol Biol. 2011 May;125(1-2):95-104. doi: 10.1016/j.jsbmb.2010.11.004. Epub 2010 Nov 16. J Steroid Biochem Mol Biol. 2011. PMID: 21087665 Free PMC article. Review.
-
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.Cancer Res. 2015 Apr 1;75(7):1413-22. doi: 10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3. Cancer Res. 2015. PMID: 25649766 Free PMC article.
-
AKR1C3 as a target in castrate resistant prostate cancer.J Steroid Biochem Mol Biol. 2013 Sep;137:136-49. doi: 10.1016/j.jsbmb.2013.05.012. Epub 2013 Jun 6. J Steroid Biochem Mol Biol. 2013. PMID: 23748150 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials